(RTTNews) - Stereotaxis, Inc. (STXS), a global leader in surgical robotics for minimally invasive interventions, announced on Monday that it has received European CE Mark approval for its MAGiC ablation catheter.
The MAGiC catheter is a robotically-navigated magnetic ablation catheter designed for cardiac ablation procedures to treat arrhythmias.
The catheter features advanced design enhancements for improved navigation, consistent contact forces, stability, and better data feedback to aid physicians during procedures.
With the CE Mark approval, the MAGiC catheter is now authorized for use in Europe for delivering local lesions in cardiac tissue to treat arrhythmias.
Stereotaxis has invested significant resources in the development, testing, and clinical research of the catheter, and early clinical experiences in Europe support broad adoption.
Stereotaxis is optimistic that the approval of MAGiC will be a key milestone in its effort to advance robotics in electrophysiology and endovascular surgery.
Following the announcement, the company's shares saw an uptick, signaling strong investor confidence in this innovative technology.
Currently, STXS is trading at $2.37 up by 8.44%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
